Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Prepaid research and development expenditures

Other financials

Income statement

See full
Revenue-—
Operating income-$65.6M-81.2%
Net income-$189.4M-201%
EPS (diluted)-$0.24-167%

Balance sheet

See full
Cash & equivalents$8.2M+7.2%
Total debt$20.0M+211%
Total equity$545.9M+58.5%
Total assets$647.9M+68.8%

Cash flow

See full
Operating cash flow-$122.3M-99.9%
CapEx$245.0K-41.9%
Free cash flow-$122.5M-99.0%

Valuation

See full
Market cap$10.67B+3.3%
Enterprise value$10.68B+3.4%

Profitability

See full
Operating margin-268,266.8%-272,316pp
Net margin-271,685%-275,966pp
FCF margin-5,931.6%+4,730pp

Returns & leverage

See full
Return on equity-271%-1,725pp
Debt / equity0×0.0×
Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept smmt:ResearchAndDevelopmentPrepaidExpensesCurrent.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's prepaid research and development expenditures.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Summit Therapeutics's prepaid research and development expenditures?
Summit Therapeutics (SMMT) reported prepaid research and development expenditures of $12.32M in Q1 2026.
How has Summit Therapeutics's prepaid research and development expenditures changed year-over-year?
Summit Therapeutics's prepaid research and development expenditures increased by 89.8% year-over-year, from $6.49M to $12.32M.
What is the long-term trend for Summit Therapeutics's prepaid research and development expenditures?
Over 2 years (2023 to 2025), Summit Therapeutics's prepaid research and development expenditures has grown at a 65.1% compound annual growth rate (CAGR), from $1.47M to $4M.